ARTICLE | Company News
Rigel, Merck KGaA deal
March 8, 2010 8:00 AM UTC
Merck informed Rigel that it plans to wind down ongoing trials and return rights to R763 (AS703569). The aurora kinase inhibitor is in Phase I testing to treat cancer. Rigel granted Serono S.A. exclu...